SeaDragon, Australasia’s largest refiner and blender of high-quality, internationally certified concentrated fish oils and fractions, including Omega-3 oils, today releases its investor update. The update includes:
Read more about SeaDragon Investor Update March 2014
04 December, 2013. Link here.
ASX Announcement (link here).
Read more about Avita Medical December 2013 Half Year Report
Australasia’s largest fish-oil refiner SeaDragon (NZX: SEA) announces a new raw material supply agreement has been signed that will underpin its Nelson-based squalene manufacturing operations, and enable the business to seek new market opportunities in the pharmaceutical and cosmetic sectors.
Read more about SeaDragon signs significant raw material supply contract
AmpliPhi BioSciences Corporation (OTCBB: APHB), the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced that President and CEO, Philip Young will be presenting at the Cowen and Company 34^th Annual Healthcare Conference at the Boston Marriott Copley Place Hotel in Boston at 2:50 pm EST (11:50 am PST) on Monday, March 3, 2014.
Read more about AmpliPhi to Present at Upcoming Healthcare Conferences
Link to press release here.
7 January 2014: Analysis from leading healthcare fund manager BioScience Managers has highlighted the outstanding year for biotech stocks on the ASX in 2013 with an average gain of 53.6%* across...
Read more about ASX BIOTECH STOCKS SURGE 54% IN 2013
AmpliPhi BioSciences Corporation (OTCBB: APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that it has entered into a definitive stock purchase agreement to raise approximately $18 million in a private placement financing.
Read more about AmpliPhi Biosciences Announces $18 Million Private Placement
ASX announcement here.
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the “Company”) today announced that it has commenced dosing patients in the Northern Hemisphere portion of its ongoing Phase 2, randomized, double blind, placebo controlled, parallel arm clinical trial of laninamivir octanoate (LANI).